E005 Reduction in 24 hour systolic blood pressure ⩽135 MMHG is associated with greater degree of left ventricular mass regression in black patients with severe hypertension

A

1

J

1

N 9 4 PH

2

9

-

8

E

A

A-

1 A OV

R On

DtO

TI iS R

h9L

rL

.p

yT

E

R M V W

H

S W R

A M H

S R

C

B G

P

V

C H N T

s L

D B

P S

C

H

H J S A B h a h r f c h a t o d T a t t p s n o l B b a c e o p We s t e n m g o d f s m r I v m ( b p w s h ( f m a 4 y h D a < o a t a h S r a d L r p w d i t g -r ( h S “ ~ m ( h S n T b a e s r a s t t b hS hS g > h S ( b 1 1 e s 1 1 h D ( b 1 Il 8 9 e s L i ( b 1 1 e s 11 I1 f * 7 e t b sig&icant r h a L w a f b g h S r S w a w g d L r ( r n r e s C d w n a ~ L i l v m r h s b p s h n

STUDY

OF W I

A

D

A Y

A E

Mati JC*.; Suarez E*; Gomez C*; Lopez. P*; Merim del CastiOo.P*; Gil. B**; Maldonado. A** *Outpatients Specialists Center and Province Primary Care Units Jaen,.**lntemal Medicine Depmtm.ent; Granada. Spain ; V *

B

T

addition of hydrochlorothiazide (HCTZ)

Y a o

a

y in patients nonresponders to

o

y Inhibitor enalapril is commonly used However, the lack ofheneticial effect i“ CHD provided by diuretic therapy may be related to potentially antagonistic effects of this drug on other risk factors, such as adverse lipid profiles. The objetive of this study was to evaluate the eff]cacy ofdwwzmin ,once dayly dose, in comparison with HCTZ (once dayly), in patients with mild to moderate hypetiension not adequately controlled by ccmcmnitant weatmentwith ACE Inhibitor enalapril.

n r i e y

The 4 month study was conducted in 53 outpatients with mild to moderate essential hypertension not adequately controlled with enalaptil. Patients were treated randomly with a once dayly dose of enalaprii (20 I@ plus m H ( mg/day); n=26, or domzosin ( 2mg/day , and increased, n d the dose up to 4mglday). Blood pressure, total serum cholesterol, LDL-chol, HDL-chol, baseline glycemia, serum creatinine, uric acid, sodium potassium and urcawere measure at baseline and at the end of the study. All side effects that occured during the course of the study were documented.

B B

Both groups showed asigniticant decre&sein SBP and DBP, being greater in those patients treated with enalapril+ doxazosin. (V DBP= - 16.0f15.5 MIldf8; V SBP= - 24.7+15.5 llUllf+8) L +HCTZ (VDBP = 13.5+9.05 mmlfg ( PS0.000I); VSBP = - 18.34*10.7 mmlig (psO.0001) respectively. The doxazosin group also showed a statistically signiticam iwnelorationin the serum lipid protile (V total cholesterol= - 17.7 k 26.2 mg/dl (ps0.001); V LDL-chol= -23.4+ 31.9 mg/dl (p50.005); AHDLchol= +4.2* 9.6 mg/dl (PsO.05); No significant changes were observed on the rest of parameters.

p

Conclusions: Tle combination ofdoxazosin and enalapril has a pronounce amihypmensive effect and has a favorable influence on serum lipid profile compared with HCTZ. K

W

D

H

h

e

~

y y

E

E A

N

G

F

E S

W

L t L I C M U T L A S L H ( w c o t c c s A B C M a V T m o w c t r b p ( o d a m w t c a f I 4 ( a n G ( 3 a p a 4 w p a s d ( b 1 a 1 m t e a4 p r w r a o f t w L Nf w C v d a t t p t e w 1 1 1 1 a 1 w m 2 ha t l i m I v t e w 1 1 a w a a w c f v 1 t 2 p ( f w c t s t a 1 p t ( +S c f 1 t 1 /1 +4 a 1 +1 /1 +3 m t La Ng r ( t r b g p > 0 f t s - S a f t D c f v 1 + 1 /9 +7 a 1 +1 /8 t 6 m ( g p< / p <0 w e t t g p <0 / p < 0 v l m v R ( w f D v < m a s D v h t n t e w 1 r 1 1 w 5 a 7 t La Ng BP a s l a a ( p=0 F t 6 w t t Ng a a a 1 w t LS R p w g s b g t t f p d o w w D a b a e l r t m t t c t t p w c t L a e h f c b v p e d a t o r s p b g D b t t ~ w r t m a t r t c s t i a w i a t w ao c a f c K W c a I n G LA

M

MV

R a T

H T

M

f

S

E

ACE

I

L M O R G

PP

O

E O T H

Y

L

A R

P

A

A

mS

s (

N

MA Ncwaz, ‘NNA Nawal. FaculhofMcdicinc. International Manic Univemit>. Pahang DM. ‘ of Biochemistry, Univemiti Kcbangsaan Malaysia. a Kuala Lumpur, Mala?sia. Tlc aim of tbis study was to determine the effects of y-Tocotrienol on hpid pcrowdation and total antiomdant status of spontaneously b>pertcnsiw rats (SHR) and comparing with that of normal Wistar K)oto (WKY) rats. SHR were divided into four different groups name!), hypertensive control (HC). o n trcauncnt withy mcooienol [5 mglkg diet (71). 30 mgfraflda>(Y2)and 150 mgikg diet (/3). WKY rats were used as normal conmol @). Blocd pressure were recorded from tbc tail b!, physiogmph every fortnigbtl}’fOr OWd~-@iOnOf the study pericd oftfuee montbs. At the end of the trial, animals wme sacrificed and measurement of plasma total antioxidant status using Randox kit. plasma supcroxide dismutase (SOD) actwity also via Randox kn and plasma lipid peroxide Ie,el h} spectrofluoromeoy mere carried out following well established methods. Data were analysed for statistical signtiicance \ia Students’ t-test and Pearson”s correlation test. The computer programme STATISTICA was used for all analysis. From our study it was found hat lipid peroxides were si@ticanOy higher m hypertensive plasma compared to that of normal rats (N=O.066+0.009 nmol malondialdeh~de (MDA) equivalenthd, HC= 0.1316+0.008 nmol MDA e P=O00) SOD acti}ity was sigmiticantlyloner i“ &pertemive tban nomml rats (N=148 58+29.S6 U/ml. HC=I 10.08+14.36 U/ml : P=O.014). Before treatment. total anoodant status was higher m normal than h>pertensi$e rats but o not significant. Atter three months of antioxidant trial with y-mc.m.rienol,it was found that all tie treated goups have reduced plasma lipid peroxides concenlralion but was 0111>significant for group ./1 (71:0.1 11+0.03 MDA equib.lmt, HCO. t31*0.02 MDA equiv.lml : P=0.030). AO the hex mcated gro”ps showed improve total antioxidmt status (FO.001) si~iticantly. All tbe gToups sbmwd significant improvement in tbeir S activit} (Yl: P=O.OfJO,72 P=01323. Y3: P=O.OfJO).Correlation studies showaJ that. In t g l p h s p r w b pressure in groups 71(1=0.75. P=O.032) and Y2(1=0.846, P= OO04).For SOD and TAS a significant ncgati}c comelationwere found with bled pressure in .?0 the three groups. fn conclusion it was found that antioxidant supplement of.ptccokienol ma): prevent dew[opment of increased blood pressure bj reducing lipid peroxides as well as enhancing total antioxidant status including S activity

r n o

n m

o

e

a i

e t

o i

K

W

T p

S T

d A

F s

r

L

nn o n

n